1	2	3
	(4) M/s. Lyka Labs.	Pending
	(5) M/s. Merind	Pending
(iii) *Calcutta High Court*	(1) M/s. Carews	Pending
	(2) M/s. Dolphin	Pending
(iv) *Ahmedabad High Court*	(1) M/s. Cadila	Pending

The Writ Petitions are mainly against the prices fixed by the Govt. and/or notice for recovery of the tentative liability of the Company, issued by the Govt. The Counter-affidavits have yet to be filed by the Govt. in the case of M|s. Lika Labs., M/s. Merind, M|s. Dolphin and M(s. Cadila and these are being expedited.

(h) and (i) The matter is being pursued.

Price of Flucort Range formulations

3052. SHRIMATI RATAN KUMARI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that contrary to the Government decision price of Flucort Range of formulations has been increased by using a small scale sector unit as an intermediary;

(b) if so, the name of the small scale unit and the percentage of price increase in each pack and strength;

(c) what is the price being charged on Flucort range of finished medicines based on the stocks with chemists and since when price increase has been put into effect;

(d) whether it is a fact that new price amounts to over-charging the consumer by rupees four crores per annum; and

(e) what steps Government have taken to pass orders for seizure of stock and prosecution of the management for open de finance?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) No such instance has come to the notice of Government.

(c) to (e) The State Drugs Controller has been asked to verify as to when the company had implemented the prices fixed by the Government in respect of Flucort range of formulations.

Indication for using Glipizide

3053. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1669 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what is the indication for which Glipizide is used;

(b) what are the names of the producers of Glipizide and what was the production of each during the last three years year-wise;

(c) whether it is also a fact that Glipizide is under price control;

(d) whether it is also a fact that Glybenclamide is also used for same indication;

(e) if so, on what basis this drug has been decontrolled and what are the criteria adopted;

(f) whether it is also a fact that Pentoxyphylline is outside price control;

(g) if so, on what basis;

(h) what are the names of drugs of this producer which are outside price control and what are the names of other producers of these drugs; and

(i) what was the production of each including the producer in question during the last three years, year-wise?